Tumor angiogenesis as a therapeutic target (Q34384638)

1 August 2017

title

Tumor angiogenesis as a therapeutic target (English)

1 reference

1 August 2017

1 reference

1 reference

A Matter

1

1 reference

1 August 2017

publication date

1 October 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

6

1 reference

1 August 2017

issue

19

1 reference

1 August 2017

page(s)

1005-1024

1 reference

Angiogenesis in cancer, vascular, rheumatoid and other disease

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

1 reference

7 January 2021

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Molecular angiogenesis

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Signaling angiogenesis and lymphangiogenesis

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Signaling Vascular Morphogenesis and Maintenance

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Vascular-specific growth factors and blood vessel formation

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Crystal structure of the ligand-binding domain of the receptor tyrosine kinase EphB2

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Oligomeric structure of the human EphB2 receptor SAM domain

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Recent insights into the role of integrins in cancer metastasis.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Requirement of vascular integrin alpha v beta 3 for angiogenesis

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Definition of Two Angiogenic Pathways by Distinct alpha(v) Integrins

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Current status of antiangiogenic factors

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

The rationale and future potential of angiogenesis inhibitors in neoplasia

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Tumor angiogenesis--new drugs on the block

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Strategies toward the design of novel and selective protein tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Structure−Activity Relationships for a Novel Series of Pyrido[2,3-d]pyrimidine Tyrosine Kinase Inhibitors

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Matrix metalloproteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Preclinical and clinical studies of MMP inhibitors in cancer

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Discovery of CGS 27023A, a Non-Peptidic, Potent, and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in Rabbits

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470).

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Anti-angiogenic therapies in cancer clinical trials.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

The angiogenesis inhibitor TNP-470 (AGM-1470) improves long-term survival of rats with liver metastasis

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Effects of AGM-1470 and pentosan polysulphate on tumorigenicity and metastasis of FGF-transfected MCF-7 cells

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Antiangiogenic therapy of transgenic mice impairs de novo tumor growth

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Effects of angiogenesis inhibitors on multistage carcinogenesis in mice

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Increased growth and incidence of lymph node metastases due to the angiogenesis inhibitor AGM-1470

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Squalamine: an aminosterol antibiotic from the shark

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Squalamine, a novel cationic steroid, specifically inhibits the brush-border Na /H exchanger isoform NHE3.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Angiostatin: A Circulating Endothelial Cell Inhibitor That Suppresses Angiogenesis and Tumor Growth

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Suppression of Tumor Growth with Recombinant Murine Angiostatin

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Angiostatin and endostatin: endothelial cell-specific endogenous inhibitors of angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Angiostatin and endostatin: endogenous inhibitors of tumor growth

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Treatment of haemangioendotheliomas with alpha interferon

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Antiangiogenic drugs as a novel anticancer therapeutic strategy. Which are the more promising agents? What are the clinical developments and indications?

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Antiangiogenic tumour therapy: will it work?

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

A dose-finding study of zoledronate in hypercalcemic cancer patients

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Linomide blocks angiogenesis by breast carcinoma vascular endothelial growth factor transfectants

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Reduction in basic fibroblast growth factor mediated angiogenesis in vivo by linomide

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Thymidine phosphorylase is angiogenic and promotes tumor growth.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Suramin and prostate cancer: where do we go from here?

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Solution structure of acidic fibroblast growth factor bound to 1,3, 6-naphthalenetrisulfonate: a minimal model for the anti-tumoral action of suramins and suradistas

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Detectable Inhibition of Heparin-Binding Growth Factor Activity in Sera From Patients Treated With Pentosan Polysulfate

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Novel non-cross resistant diaminoanthraquinones as potential chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Effects of Thalidomide and Related Metabolites in a Mouse Corneal Model of Neovascularization

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Tecogalan sodium inhibits corneal neovascularization induced by basic fibroblast growth factor

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Interferon alfa-2a therapy for life-threatening hemangiomas of infancy

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Troponin I is present in human cartilage and inhibits angiogenesis

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Antiangiogenic activity of the cleaved conformation of the serpin antithrombin

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Alpha v integrins as receptors for tumor targeting by circulating ligands.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Chemotherapy targeted to tumor vasculature.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Targeting the tumor vasculature: Inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Down-regulation of Vascular Endothelial Growth Factor in a Human Colon Carcinoma Cell Line Transfected with an Antisense Expression Vector Specific for c-src

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

A secreted FGF-binding protein can serve as the angiogenic switch in human cancer.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Targeting an adenoviral gene vector to cytokine-activated vascular endothelium via E-selectin

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Considerations and challenges for the achievement of targeted gene delivery

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(01)01939-0

7 January 2021

10.1016/S1359-6446(01)01939-0

Identifiers

DOI

1 reference

1 August 2017

1 reference